Albertsons partnered with genomics firm Phosphorus to begin offering at-home COVID-19 test kits in select markets, with plans to expand the offering throughout September and October.
Mark Panzer, most recently Albertsons' senior vice president of pharmacy, health and wellness, is departing the company to pursue other interests, a company spokesperson said.
With plans to sell 65.8 million shares of its common stock on the New York Stock Exchange under the ticker symbol ABI, Albertsons could bring in between $1.2 billion and $1.3 billion with its initial public offering.